Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A usually high grade squamous cell carcinoma that arises from the ovary and is not associated with a germ cell tumor. The prognosis is poor.
Biomarker and diagnostic research for ovarian squamous cell carcinoma has been reported in the published literature.
2 clinical trials registered. Interventions under study include drug therapy, procedural interventions, and biologic therapy. Pipeline includes 2 PHASE2. Research is primarily sponsored by academic and government institutions.
73 publications have been identified in PubMed for ovarian squamous cell carcinoma. Research spans Case Report / Case Series (47%), Epidemiology / Natural History (15%), and Review / Meta-Analysis (11%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 34 |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 4:31 PM UTC
Disease patterns and progression | 11 | 15% |
Research summaries | 8 | 11% |
Laboratory research | 8 | 11% |
Clinical study results | 4 | 6% |
Testing and diagnosis research | 3 | 4% |
New treatment approaches | 3 | 4% |
Other research | 1 | 1% |
Li CL (2026). [PMID: 41957787](https://pubmed.ncbi.nlm.nih.gov/41957787/). *J Ovarian Res*. [Case Report / Case Series]
Dunneram Y (2026). [PMID: 41748939](https://pubmed.ncbi.nlm.nih.gov/41748939/). *Br J Cancer*. [Epidemiology / Natural History]
Gupta A (2026). [PMID: 40991421](https://pubmed.ncbi.nlm.nih.gov/40991421/). *Int J Gynecol Pathol*. [Epidemiology / Natural History]
Bertolazzi M (2026). [PMID: 41759360](https://pubmed.ncbi.nlm.nih.gov/41759360/). *Eur J Surg Oncol*. [Clinical Trial Publication]
Tamauchi S (2026). [PMID: 41531187](https://pubmed.ncbi.nlm.nih.gov/41531187/). *Cancer Sci*. [Gene Therapy / Novel Therapeutics]
Ren Y (2026). [PMID: 41474616](https://pubmed.ncbi.nlm.nih.gov/41474616/). *Cancer Med*. [Epidemiology / Natural History]
Atienza AE (2026). [PMID: 41796476](https://pubmed.ncbi.nlm.nih.gov/41796476/). *Int J Gynecol Cancer*. [Clinical Trial Publication]
Hamdaoui Y (2026). [PMID: 41743388](https://pubmed.ncbi.nlm.nih.gov/41743388/). *Oxf Med Case Reports*. [Case Report / Case Series]
Büyücek S (2026). [PMID: 41519763](https://pubmed.ncbi.nlm.nih.gov/41519763/). *BMC Cancer*. [Diagnostic / Biomarker]
Guo F (2026). [PMID: 41659711](https://pubmed.ncbi.nlm.nih.gov/41659711/). *Front Oncol*. [Case Report / Case Series]